Radiopharmaceutical firm Clarity Pharmaceuticals and imaging agent developer ImaginAb are collaborating to develop new targeted theranostic products for a range of cancer types.
Specifically, the companies said they will use Clarity's copper chelators to develop minibody and cys-diabody radiopharmaceutical products that utilize copper-64 for diagnosis and copper-67 for therapy.
ImaginAb has previously coupled radioisotopes with minibodies and cys-diabodies for PET imaging of molecular targets. The partnership marks ImaginAb's entry into the field of targeted radiotherapy, according to the vendor.
